Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Proteolysis-targeting chimera (PROTAC) technology represents a novel and promising
modality for targeted protein degradation with transformative implications for the clinical …

With advances in chemically induced proximity technologies, heterobifunctional modalities
such as proteolysis targeting chimeras (PROTACs) have been successfully advanced to …

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …

Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is implicated in a broad range of
diseases due to its role as the ultimate effector of necroptosis and has therefore emerged as …

Targeted protein degradation (TPD) is an emerging technique for protein regulation.
Currently, all TPD developed in eukaryotic cells relies on either ubiquitin-proteasome or …

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug
discovery and development, offering a promising avenue to tackle challenging therapeutic …

Cell division in eukaryotes is a highly regulated process that is critical to the life of a cell.
Dysregulated cell proliferation, often driven by anomalies in cell Cyclin-dependent kinase …

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention
over the last 10 years, representing a burgeoning therapeutic approach with the potential to …

The CDK8–cyclin C complex is an important anti-tumor target, but unlike CDK8, cyclin C
remains undruggable. Modulators regulating cyclin C activity directly are still under …